CSI Introduces Stealth 360 Peripheral OAS in Europe


November 13, 2018—Cardiovascular Systems, Inc. (CSI) announced the first commercial use in Europe of the company's Stealth 360 peripheral orbital atherectomy system (OAS).

The initial cases were performed by Reza Asady, MD, and Ingo Benz, MD, at St. Vincenz Hospital in Köln, Germany.

In the company's announcement, Tobias Achenbach, MD, Head of the Radiology Department at St. Vincenz Hospital, commented, “CSI’s minimally invasive orbital atherectomy technology allows physicians to gently modify calcified plaque and enables peripheral revascularization for patients with severely calcified arteries. The introduction of orbital atherectomy in Germany greatly improves the treatment options for my patients suffering from peripheral artery disease (PAD).”

Professor Dierk Scheinert, MD, stated, “Of those suffering from PAD, many progress to critical limb ischemia (CLI), the most severe and potentially deadly form of PAD. If left untreated, CLI can lead to amputation. The unique ability of orbital atherectomy to safely treat calcified peripheral lesions, both above and below the knee, will allow physicians in Germany to help a very challenging patient population.” Prof. Scheinert is Head of the Department of Medicine, Angiology, and Cardiology, at Park-Krankenhaus Leipzig, and Head of the Department of Angiology, at the University Hospital Leipzig Heart Center, in Leipzig, Germany.

In July 2018, CSI announced that it had signed an exclusive international distribution agreement with OrbusNeich to sell its coronary and peripheral OAS outside of the United States and Japan.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.